Thermo Fisher Scientific (TMO) Other Accumulated Expenses (2009 - 2026)

Thermo Fisher Scientific has disclosed Other Accumulated Expenses across 18 years of filings, most recently posting $3.7 billion for Q1 2026.

• Quarterly Other Accumulated Expenses rose 22.24% year-over-year to $3.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 billion (up 22.24% YoY) and the FY2025 annual result came in at $3.3 billion, up 4.06% from the prior year.
• Other Accumulated Expenses rose to $3.7 billion in Q1 2026, from $3.3 billion in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $3.7 billion in Q1 2026 and troughed at $2.8 billion in Q3 2023.
• A 5-year average of $3.2 billion and a median of $3.2 billion in 2024 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses jumped 58.89% — and 2023, when it dropped 11.17%.
• Tracing TMO's Other Accumulated Expenses over 5 years: stood at $3.4 billion in 2022, then decreased by 3.22% to $3.2 billion in 2023, then slipped by 1.45% to $3.2 billion in 2024, then gained by 4.06% to $3.3 billion in 2025, then rose by 10.96% to $3.7 billion in 2026.
• Business Quant data shows TMO's Other Accumulated Expenses at $3.7 billion in Q1 2026, $3.3 billion in Q4 2025, and $3.2 billion in Q3 2025.